KalVista Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KALV Nasdaq 2836 www.kalvista.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - Jan 8th, 2026 2:05 pm
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Dec 22nd, 2025 4:00 am
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - Dec 4th, 2025 11:09 am
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment - Dec 3rd, 2025 2:09 pm
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Nov 18th, 2025 4:16 am
Ekterly Momentum Shows Royalty Asset Value For DRI Healthcare Trust, Says Stifel Canada - Nov 12th, 2025 10:32 am
KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... - Nov 11th, 2025 2:02 pm
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Nov 10th, 2025 2:30 pm
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting - Nov 6th, 2025 6:01 am
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 5th, 2025 5:00 am
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - Nov 3rd, 2025 5:00 am
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Oct 30th, 2025 5:00 am
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - Oct 6th, 2025 2:00 pm
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - Oct 6th, 2025 5:00 am
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 3rd, 2025 5:00 am
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - Oct 2nd, 2025 5:00 am
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Sep 26th, 2025 5:00 am
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Sep 24th, 2025 8:52 pm
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - Sep 24th, 2025 2:01 pm
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema - Sep 19th, 2025 5:00 am